Background. Familial amyloid polyneuropathy (FAP) is an autosomal dominant disease caused by a point mutation in the gene encoding transthyretin, which is secreted by the liver. Orthotopic liver transplantation (OLT) has been proposed to prevent disease progression. Little is known about long-term changes in renal function and lesions after OLT. Methods. The renal function of 33 patients with FAP was evaluated (proteinuria, serum creatinine, creatinine clearance) before OLT and over a period of at least 5 years afterwards. A pre-transplantation renal biopsy was performed in 14 patients and a follow-up biopsy in eight patients. Results. Before transplantation, mean serum creatinine concentration was 86 mmol/l (47-126 mmol/l) and creatinine clearance was 71.9±31.6 ml/min/1.73 m 2 . Proteinuria was detected in 54% of patients (0.3-4 g/day). Pre-transplant renal biopsies (n ¼ 14) revealed glomerular, tubular and vascular amyloid deposits in 90, 58 and 66% of patients, respectively. Eleven patients (33%) died after OLT. Death occurred most frequently in patients having weight losses >7 kg (P<0.05). After transplantation, 25 patients (76%) suffered acute renal failure but only one required dialysis. One month after transplantation, the mean serum creatinine concentration was 134.1±73 mmol/l and remained constant during follow-up. Eight patients underwent a second renal biopsy 2 years after transplantation. No significant changes in deposits or renal toxicity due to calcineurin inhibitors were detected.
Introduction
Familial amyloid polyneuropathy (FAP) is an autosomal dominant disease caused by a point mutation in the gene encoding transthyretin [1, 2] . In most cases, the 30th amino acid, a valine, is replaced by a methionine, but other point mutations have also been described [3] . The mutated protein, which is mainly produced by the liver, adopts a b-sheet structure and accumulates in various tissues, inducing amyloid deposition [4] , mostly in nerves. This leads to irreversible and progressive peripheral and autonomic neuropathy [5] . The deposits also induce orthostatic hypotension, anhydrosis and sexual impotence. Amyloid deposition has also been documented in the skin, heart, gastrointestinal track and kidneys [5] [6] [7] . The symptoms of the disease generally appear between the ages of 10 and 30 years. They then progress irreversibly and result in death within 5-10 years, following the development of profound muscular atrophy, severe autonomic neuropathy and malnutrition [8] .
Liver transplantation has been proposed to treat this fatal disease because the liver is the principal site of synthesis of the mutated protein [9] . Liver transplantation results in the stabilization of neurological symptoms but not in a significant improvement [5, 10] . Therefore, it has to be performed early in the course of the disease, before the development of severe symptoms and, particularly, malnutrition-which is associated with high morbidity and mortality [8] .
Renal involvement is frequent, as in other types of amyloid deposition [6] , but renal symptoms are less severe in FAP [7, 11] . Lobato et al. [7] recently reported renal involvement in 14 patients investigated before liver transplantation: only half of these patients had proteinuria or microalbuminuria. Deposits were observed in glomeruli, along the tubular basement membrane and in vessel walls. Renal function was not severely impaired before orthotopic liver transplantation (OLT), but its subsequent natural evolution was not documented.
Although Carvalho et al. [12] reported decreased proteinuria after liver transplantation, the evolution of renal function and kidney deposits is not known. Liver transplantation is associated with substantial decreases in the amounts of mutated protein produced and reduction of amyloid deposition, and it may affect the natural course of kidney lesions. However, the renal lesions observed in FAP may be worsened by immunosuppressive treatments based on calcineurin inhibitors. Indeed, recent reports have demonstrated substantial renal toxicity following liver transplantation even in the absence of prior nephropathy. As renal involvement is frequent in patients with FAP, it is of particular interest to investigate changes in renal function in the short and long term, following the introduction of calcineurin inhibitors. We report the results of our study of changes in renal histology and function in 33 patients suffering from FAP. The patients were followed for at least 5 years after liver transplantation.
Subjects and methods

Patients
We studied 33 patients (Table 1) between March 1993 and December 1996. 32 had undergone liver transplantation, and one patient, with impaired renal function and severe vascular and glomerular amyloid deposits, had had a combined liver-kidney transplantation (patient 15, Tables 1 and 2) . Of the cohort, 31 patients were from Portugal, one from France and one from Congo; 14 were female (42%) and 19 male (58%). The mean age at the time of diagnosis was 35 years (23-59)-37.5 years for women and 33.6 years for men. The mean duration of symptoms before transplantation was 5 years (1.5-10). 
Diagnosis of FAP
All of the patients had a history of familial polyneuropathy. The diagnosis of polyneuritis was confirmed by neuromuscular biopsies. Amyloid deposition was assessed by Congo red staining, and the nature of the deposits was determined by immunostaining with a rabbit polyclonal antibody against human transthyretin (Dako). Mutations in the gene encoding transthyretin were identified by the polymerase chain reaction. All patients were found to have a mutation consisting of the replacement of the valine-30 by a methionine.
Renal function and histology
Renal evaluation was performed before liver transplantation and 15 days, 1, 3, 6 months and annually for 5 years afterwards. Daily proteinuria, haematuria and serum creatinine concentration were measured and creatinine clearance calculated, according to the Cockcroft-Gault formula, in all patients. The glomerular filtration rate (GFR) in 19 patients was assessed by determining chromium-51-EDTA clearance. Liver function before transplantation, based on serum albumin concentration and prothrombin time, was normal in all patients except three, who had low serum albumin concentrations related to malnutrition. These three patients did not have daily urinary protein excretions above 0.3 g/day.
A transjugular renal biopsy was performed before liver transplantation in 14 patients (during pre-transplantation evaluation) and after transplantation in those (n ¼ 8) who had proteinuria or severe or moderate renal dysfunction. In the first few patients without renal symptoms, we also performed a renal biopsy before introducing calcineurin inhibitors for OLT, and because renal involvement with the disease had not been well documented at that time. The transjugular method was used to avoid the haemorrhagic complications of transparietal biospy, which have been reported to be more frequent in patients with amyloidosis. In the present series, no complication of transjugular biospy was observed. Biopsy samples were fixed in alcoholic Bouin or immediately frozen for immunofluorescent staining. Amyloidosis was assessed by Congo red staining. Transthyretin A deposits were confirmed using the antitransthyretin polyclonal antibody on cryosections. Two pathologists independently carried out semi-quantitative analyses of amyloid deposits using the following scale: 0, absence of Congo red deposit; þ, small deposits with a weak Congo red staining; þþ, moderate deposits with strong Congo red staining; and þþþ, large deposits with very intense Congo red staining. The scores of amyloid deposits established by the two pathologists were averaged.
Renal samples were analysed also using haematein eosin safran, periodic acid-Schiff and Masson's trichrome stainings. Hyalin deposits observed with these stains but negative to Congo red were considered to have resulted from calcineurin inhibitor toxicity.
Immunosuppressive regimen for liver transplantation
All but one patient received corticosteroids and cyclosporin A. The target trough levels of cyclosporin were 130-180 ng/ml. One patient was treated with tacrolimus (trough level: 5-9 ng/ml). For five patients, cyclosporin A was subsequently replaced by tacrolimus because of acute liver rejection. Acute rejections were treated with high-dose pulses of corticosteroids and steroid-resistant rejections with OKT3.
Statistical analysis
Parametric (unpaired Student's t-test) and non-parametric (Yate's corrected chi-square) tests were used for statistical analyses. Results are expressed as a mean ± SE of the mean. A P<0.05 was considered to be statistically significant. Patient survival was determined according to a KaplanMeier analysis. Correlation was performed using the ANOVA test with StatviewÕ software. Glomeruli Vessels Interstitium Glomeruli Vessels Iinterstitium
Amyloid deposits were scored from 0 to þþþ with Congo red staining. nd, not done.
Renal function in FAP patients after liver transplantation
Results
Renal function
All patients underwent renal function evaluation before liver transplantation ( (Figure 1 ).
Blood pressure and proteinuria
None of the patients had arterial hypertension before OLT. On the contrary, 13 patients (39.4%) had orthostatic hypotension, along with associated symptoms in 10 patients. Proteinuria was detected in 54% of patients, with values ranging from 0.1 to 3.8 g/day; the mean value was 0.8±1 g/day. In most of these patients (72%), urinary protein output was below 1 g/day. Proteinuria did not correlate with renal function, age or duration of neurological symptoms.
Renal histology
Of the transjugular renal biopsy performed on 14 patients (Table 2) , only 12 were interpretable. A mean of 10 glomeruli was observed per biopsy section (0-16). Amyloid deposits were detected in all cases. Glomerular deposits were present in 90% of the biopsy samples that contained glomeruli (Figure 2) . In most cases, glomerular deposits were abundant. For six of the nine patients with glomerular deposits, protein was negative or below 0.5 g in 24 h urine samples (see Tables 1 and 2 ). Amyloid deposits were detected also in small vessels in 10 cases (83%) and along the basal membrane of tubules in 58%. Congo red-positive deposits did not stain with monoclonal anti-kappa or anti-lambda light chain antibodies or antibodies against AA protein. In some cases, the presence of transthyretin in the deposits was confirmed by staining with an anti-transthyretin antibody (data not shown).
Patient's outcomes after OLT
Liver transplantation was performed within a mean of 60 months after the diagnosis of FAP (18-600). The mean duration of follow-up after transplantation was 63.6±36.8 months. All but one of the 12 patients (36%) who suffered an acute rejection episode responded to corticosteroid treatment; in addition, for five of these patients cyclosporin A was replaced by tacrolimus. Patient survival rates were 82% at 1 year and 76% at 2 years after transplantation (Figure 3) . Of the cohort, 11 (33%) died, six within the first 6 months after transplantation: two died from septic shock, two from Pneumocystis carinii infection and one from acute respiratory failure. One patient died later from a post-transplantation lymphoproliferative disorder, one patient from a sudden cardiac arythmia, one from malnutrition and one from myocardial infarction. For two patients, the cause of death is unknown. The risk of death was not associated with sex, age, renal function or the date of transplantation. Patients who died tended to have a lower body mass index (BMI) than those who survived, although this difference was not statistically significant (18.9±1.5 vs 22.9±1.4 kg/m 2 , P ¼ 0.087). Surviving patients had lost less than 7 kg of their body mass, whereas patients who died had larger mass reductions (P<0.05). Although creatinine clearance was not associated with death, it correlated with BMI (r 2 ¼ 0.745), suggesting that this variable may be a marker of the progression of the disease.
Renal function follow-up
After transplantation, 25 patients (76%) had acute renal failure, defined by an increase in serum creatinine of more than 30% over the baseline value-19 patients (57.7%) displayed increases in serum creatinine of more than 50%. Only one patient required dialysis, transiently, for acute renal failure. The mean serum creatinine concentration rose to 159.6±76.0 mmol/l 15 days after transplantation, and was 134.1±73.0 mmol/l 1 month after transplantation. Thus, serum creatinine concentration was 30% above baseline during the month following transplantation ( Figure 4A ). Thereafter, serum creatinine remained stable in 30% of patients, whereas in 60% it was slightly above their basal values (by <30%); for the other 10%, it was more than 100% higher. No correlation was found between the increase in serum creatinine concentration, the initial GFR and the grade of amyloid deposition.
The mean follow-up period for the surviving patients was 86.7±14.9 months; the renal function of all of them was tested for a period of 5 years after transplantation. Creatinine clearance was determined each year after transplantation. It remained constant throughout the follow-up, except during the first month after transplantation ( Figure 4B) .
The mean value of serum creatinine was 111 mmol/l at 1 year and 107 mmol/l at 5 years. Similarly, creatinine clearance (by the Cockcroft-Gault formula) did not change significantly during follow-up: it varied from 59 ml/min/1.73 m 2 at 1 month after transplantation to 72 ml/min/1.73 m 2 at 5 years (not significant). In addition, the renal functions of patients who died after transplantation remained unchanged while they survived, except for the two patients who developed acute tubular necrosis due to septic shock. Proteinuria was not affected by transplantation. A second biopsy was performed on eight patients at least 2 years after transplantation. Of them, six had been biopsied before transplantation (Table 2) . Amyloid deposits were still present in all cases, with a similar pattern and a similar grade of deposition in each case. For two patients, glomeruli were not available in the initial biopsy (see patients 25 and 30, Table 2 ). Glomerular deposits were observed in five of the six samples containing glomeruli (83.3%). Semiquantitative analysis did not show significant regression of amyloid deposits. No additional lesion, which might have been induced by calcineurin inhibitors, was observed. Glomerular sclerosis was observed only in one follow-up biopsy, which did not display glomerular amyloid deposits (patient 26, Table 2 ).
Discussion
FAP is associated with point mutations in the gene encoding transthyretin, also known as pre-albumin, leading to the deposition of this protein in several tissues, including nerve, gastrointestinal tract, heart and kidney [6, 11] . Several mutations in the transthyretin gene have been shown to be associated with FAP. They include mutations affecting the 30th (Met30), 33rd (Leu33), 34th (Thr34), 36th (Pro36), 71th (Ala71), 89th (Gln89) and 90th (Asn90) amino acids [2] . Experiments in transgenic mice have supported the association of the disease with mutations in the prealbumin gene; the production of mutated human pre-albumin correlated with the occurrence of polyneuropathy [13, 14] . In humans, for unknown reasons, symptoms of the disease begin to appear after the second decade and lead to death after 8-13 years [15] . Treatment by anti-human transthyretin immunoabsorption has been attempted [16] . However, the most widely used strategy to reduce the concentration of the mutated protein is liver replacement, as transthyretin (wild-type and mutated form) is mainly secreted by the liver (95%), a small fraction being synthesized by the choroid plexus [5] . In our population, liver transplantation was associated with a high risk of death. We observed that major weight loss, over 7 kg (mainly due to diarrhoea), was also associated with a high mortality rate. It is possible that transplantation performed early, particularly before the start of malnutrition, would be associated with a better outcome [8, 15] .
Nephropathy has also been reported in patients with FAP. However, in contrast to what is observed with other types of amyloidosis, renal symptoms are not preponderant. In our study and in a Portuguese report [7] , only a few patients manifested a nephrotic syndrome despite the presence of severe glomerular lesions. Furthermore, in biopsies performed because of renal failure but in the absence of severe proteinuria, we identified glomerular lesions with major deposits. Glomerular lesions were associated with tubular and vascular lesions as previously described [7] . The reason why glomerular deposits are not associated with severe renal symptoms, and particularly with high proteinuria, is not known. In the study by Lobato et al. [7] also, the levels of proteinuria were very low, despite the presence of moderate to severe glomerular amyloid deposition. Glomerular deposits are observed as soon as pathologic microalbuminuria can be detected. Thus, microalbuminuria appears as the first stage of clinical amyloid nephropathy, resulting in overt nephropathy in half of the patients; therefore, all patients with FAP should be screened for it [17] .
Our patients displayed moderate renal dysfunction with a GFR of 73.4 ml/min/1.73 m 2 . The study by Steen et al. [18] indicates that the GFR is frequently affected in FAP. In our population, creatinine clearance (by the Cockcroft formula) significantly correlated with 51-chromium-EDTA clearance. In contrast, serum creatinine concentration did not appear to be a good marker of renal function in this population suffering from malnutrition. It may be used, however, to follow changes of renal function, since the BMI remains constant after OLT, as in the patients in our study.
Liver transplantation is associated with a rapid, substantial and prolonged decrease in the plasma concentration of the mutated protein [5] . After transplantation, a small amount of the protein continues to be detected in the plasma [5] , corresponding to the fraction produced by the choroid plexus. The symptoms observed before transplantation are stabilized by the procedure but do not regress [5, 10] . Other studies have reported partial improvement of neurological symptoms [19, 20] . Rydh et al. [11] did not observe the fixation of a radio-labeled P-substance in two patients, suggesting that amyloid deposits had regressed 2 years after transplantation. However, our results, which include a small number of patients who underwent follow-up renal biopsies up to 2 years after transplantation, suggest that renal deposits did not decrease substantially after transplantation. At the same time, neither these amyloid deposits nor the proteinuria and the renal dysfunction increased significantly during our follow-up. Overall, our data suggest that liver transplantation interrupts active amyloid deposition and stabilizes renal involvement. However, those preexisting amyloid deposits are themselves very stable and are not easily degraded by renal cells (mesangial cells, epithelial cells, macrophages).
Beyond the first month, renal function remained stable in our patients for at least 5 years after transplantation. Serum creatinine concentration increased soon after transplantation (within the first 15 days), but did not further increase subsequentlydespite extensive amyloid deposits being observed in glomeruli and vessels. Interestingly, the use of calcineurin inhibitors, which have been demonstrated to be toxic to kidneys, did not affect renal function. This suggests that, in the absence of severe renal failure (creatinine clearance >40 ml/min/1.73 m 2 ), liver transplantation can be performed without concomitant renal transplantation. However, if renal function is severely affected, combined liver-kidney transplantation may be necessary.
In conclusion, we confirm that renal lesions are frequently observed in the FAP population, but are not associated with severe proteinuria. Although liver transplantation in FAP does not affect renal amyloid deposits, it prevents or slows the progression of renal dysfunction by inhibiting amyloid synthesis. OLT may be performed in patients with mild and moderate renal dysfunction (creatinine clearance >40 ml/min) and in the absence of severe nephrotic syndrome.
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